Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study

Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study

Background: This study was conducted to evaluate the efficacy and safety of docetaxel/S-1 (TS) compared with docetaxel/capecitabine (TX) as a first-line treatment for advanced breast cancer. Methods: Patients with advanced metastatic breast cancer were randomly divided into the TS group (n = 54) and...

Full description

Bibliographic Details
Main Authors: Nilupai Abudureheiyimu, Yun Wu, Qing Li, Pin Zhang, Fei Ma, Peng Yuan, Yang Luo, Ying Fan, Shanshan Chen, Ruigang Cai, Qiao Li, Yiqun Han, Hangcheng Xu, Yan Wang, Jiayu Wang, Binghe Xu
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Journal of the National Cancer Center
Subjects:
Advanced breast cancer
Maintenance therapy
Docetaxel
Capecitabine
S-1
Online Access:http://www.sciencedirect.com/science/article/pii/S2667005423000285

Internet

http://www.sciencedirect.com/science/article/pii/S2667005423000285

Similar Items